Dyadic International, ERS Genomics announces CRISPR/Cas9 license

ERS Genomics and Dyadic International (DYAI) announced a CRISPR/Cas9 license agreement. This agreement grants Dyadic access to ERS’ CRISPR/Cas9 patent portfolio. “Access to ERS Genomics’ foundational CRISPR/Cas9 patent portfolio expands our genetic engineering toolkit and strengthens our ability to speed up and optimize strain development across Dyadic’s proprietary C1 and Dapibus production platforms,” stated Joe Hazelton, President and COO, Dyadic Applied BioSolutions. “This agreement supports both Dyadic’s internal product pipeline and the customized production strains we develop for our partners. By integrating CRISPR-based gene editing into our development workflow, we can boost strain performance, efficiency, and adaptability, delivering greater value across the life sciences, food and nutrition, and bio-industrial sectors.”